The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease

Scientific Reports

Volumn 6, Issue 1, 2016, Pages

  Al Hilaly, Youssra K ^a,b   Biasetti, Luca ^a   Blakeman, Ben J F ^c   Pollack, Saskia J ^a   Zibaee, Shahin ^d   Abdul Sada, Alaa ^a   Thorpe, Julian R ^a   Xue, Wei Feng ^c   Serpell, Louise C ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b MUSTANSIRIYAH UNIVERSITY   (Iraq)

^c UNIVERSITY OF KENT   (United Kingdom)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; COPPER; DITYROSINE; RECOMBINANT PROTEIN; TYROSINE;

AGED; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ATOMIC FORCE MICROSCOPY; BIOSYNTHESIS; BRAIN; CHEMISTRY; DIMERIZATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LEWY BODY; MALE; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TANDEM MASS SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; BRAIN; COPPER; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LEWY BODIES; MALE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY; TYROSINE;

EID: 85020024761     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39171     Document Type: Article

References (44)

1. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nature Neurosci. 7, 492-501 (2001).
2. Wright, J. A., Wang, X. & Brown, D. R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 23, 2384-2393 (2009).
3. Celej, M. S. et al. Toxic prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet structure. The Biochemical journal 443, 719-726 (2012).
4. Winner, B. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America 108, 4194-4199 (2011).
5. Monsellier, E., Bousset, L. & Melki, R. alpha-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane. Scientific reports 6, 19180 (2016).
6. Zhou, C., Huang, Y. & Przedborski, S. Oxidative stress in Parkinson's disease: A mechanism of pathogenic and therapeutic significance. Annals of the New York Academy of Sciences 1147, 93-104 (2008).
7. Moreira, P. I. et al. In Oxidative Stress and Neurodegenerative Disorders (eds G. Ali Qureshi & S. Hassan Parvez) 267-281 (Elsevier Science B.V., 2007).
8. Cuajungco, M. P. et al. Evidence that the beta-Amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. The Journal of biological chemistry 275, 19439-19442 (2000).
9. Al-Hilaly, Y. et al. A central role for dityrosine crosslinking of Amyloid-beta in Alzheimer's disease. Acta Neuropathologica Communications 1, 83 (2013).
10. Cole, N. B. et al. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. The Journal of biological chemistry 280, 9678-9690 (2005).
11. Paik, S. R., Shin, H. J. & Lee, J. H. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Archives of biochemistry and biophysics 378, 269-277 (2000).
12. Pennathur, S., Jackson-Lewis, V., Przedborski, S. & Heinecke, J. W. Mass spectrometric quantification of 3-nitrotyrosine, orthotyrosine, and o, o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine-Treated mice, a model of oxidative stress in Parkinson's disease. The Journal of biological chemistry 274, 34621-34628 (1999).
13. Pennathur, S., Jackson-Lewis, V., Przedborski, S. & Heinecke, J. Marked elevations of 3-nitrotyrosine and dityrosine in mice with MPTP-induced Parkinson's Disease. Free Radical Bio Med 27, S141-S141 (1999).
14. Ruf, R. A., Lutz, E. A., Zigoneanu, I. G. & Pielak, G. J. Alpha-Synuclein conformation affects its tyrosine-dependent oxidative aggregation. Biochemistry 47, 13604-13609 (2008).
15. Dexter, D. T. et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. Journal of neurochemistry 52, 1830-1836 (1989).
16. Riederer, P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. Journal of neurochemistry 52, 515-520 (1989).
17. Borsarelli, C. D. et al. Biophysical properties and cellular toxicity of covalent crosslinked oligomers of α -synuclein formed by photoinduced side-chain tyrosyl radicals. Free Radical Biology and Medicine 53, 1004-1015 (2012).
18. Krishnan, S. et al. Oxidative dimer formation is the critical rate-limiting step for parkinson's disease α -synuclein fibrillogenesis. Biochemistry 42, 829-837 (2003).
19. Dexter, D. T. et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 4), 1953-1975 (1991).
20. Eliezer, D., Kutluay, E., Bussell, R. J. & Browne, G. Conformational properties of alpha-synuclein in its free and lipid associated states. Journal of molecular biology 307, 1061-1073 (2001).
21. Serpell, L. C., Fraser, P. E. & Sunde, M. X-ray fiber diffraction of amyloid fibrils. Methods Enzymol 309, 526-536 (1999).
22. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of molecular biology 273, 729-739 (1997).
23. Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
24. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proceedings of the National Academy of Sciences of the United States of America 97, 4897-4902 (2000).
25. Tanner, C. M. & Goldman, S. M. Epidemiology of Parkinson's disease. Neurologic clinics 14, 317-335 (1996).
26. Pall, H. S. et al. Raised cerebrospinal-fluid copper concentration in parkinson's disease. The Lancet 330, 238-241 (1987).
27. Barnham, K. J. & Bush, A. I. Metals in Alzheimer's and Parkinson's diseases. Current opinion in chemical biology 12, 222-228 (2008).
28. Theillet, F. X. et al. Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature 530, 45-50, doi:10.1038/nature16531(2016).
29. Lucas, H. R., Debeer, S., Hong, M. S. & Lee, J. C. Evidence for copper-dioxygen reactivity during α -synuclein fibril formation. Journal of the American Chemical Society 132, 6636-6637 (2010).
30. Souza, J. M., Giasson, B. I., Chen, Q. P., Lee, V. M. Y. & Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers - Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. Journal of Biological Chemistry 275, 18344-18349 (2000).
31. Kaylor, J. et al. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J Mol Biol 353, 357-372 (2005).
32. Vilar, M. et al. The fold of α -synuclein fibrils. Proceedings of the National Academy of Sciences 105, 8637-8642 (2008).
33. Morris, K. L. et al. The Structure of Cross-β Tapes and Tubes Formed by an Octapeptide, α Sβ 1. Angewandte Chemie International Edition 52, 2279-2283 (2013).
34. Tuttle, M. D. et al. Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nature structural & molecular biology (2016).
35. Roberti, M. J. et al. Quantum Dots As Ultrasensitive Nanoactuators and Sensors of Amyloid Aggregation in Live Cells. Journal of the American Chemical Society 131, 8102-8107, doi:10.1021/Ja900225w (2009).
36. Lee, C. C., Nayak, A., Sethuraman, A., Belfort, G. & McRae, G. J. A three-stage kinetic model of amyloid fibrillation. Biophysical journal 92, 3448-3458 (2007).
37. Fink, A. L. The aggregation and fibrillation of alpha-synuclein. Accounts of Chemical Research 39, 628-634 (2006).
38. Thorpe, J. R., Morley, S. J. & Rulten, S. L. Utilizing the peptidyl-prolyl cis-Trans isomerase Pin1 as a probe of its phosphorylated target proteins: Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. Journal of Histochemistry and Cytochemistry 49, 97-107 (2001).
39. Thorpe, J. R. The application of LR gold resin for immunogold labeling. Methods Mol Biol 117, 99-110 (1999).
40. Zibaee, S. et al. Human beta-synuclein rendered fibrillogenic by designed mutations. The Journal of biological chemistry 285, 38555-38567 (2010).
41. Masuda, M. et al. Cysteine misincorporation in bacterially expressed human alpha-synuclein. FEBS letters 580, 1775-1779 (2006).
42. Kato, Y. et al. Immunochemical detection of protein dityrosine in atherosclerotic lesion of apo-E-deficient mice using a novel monoclonal antibody. Biochemical and biophysical research communications 275, 11-15 (2000).
43. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. oint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26, doi:citeulike-Article-id:7955322 (1992).
44. Xue, W. F. & Radford, S. E. An imaging and systems modeling approach to fibril breakage enables prediction of amyloid behavior. Biophysical journal 105, 2811-2819 (2013).